October 25th 2024
Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
CDC Issues Alert to Address Shortage of RSV Treatment Nirsevimab
October 24th 2023Nirsevimab-alip (Beyfortus; Sanofi and AstraZeneca) is a monoclonal antibody approved to prevent against respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants under 8 months of age born during or entering their first RSV season.
Read More
Cognitive Training Programs Have No Long-Term Benefit for Children Born Very Preterm
September 13th 2023Children born at 24- through 34-weeks’ gestation could have neurobehavioral problems and developmental dysfunctions, including language, executive function, attention, and behavioral disorders.
Read More
Preventing Respiratory Syncytial Virus at a Young Age May Reduce Risk of Developing Asthma
September 12th 2023Pediatric and maternal respiratory syncytial virus (RSV) vaccines are being studied to reduce the burden of RSV, and more research is needed to understand whether this can reduce wheeze and asthma.
Read More